|
44 Companies |
|
53 Products |
|
53 Products |
|
65 Mechanisms of Action |
|
1 Trial |
|
216 News |
|
| «12345» |
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Sep 11, 2015
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2012 --> Jun 2016
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2012 --> Jun 2016 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 24, 2015
P2, N=210, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015
- Trial primary completion date, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Oct 2011 --> Feb 2012
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=225, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Oct 2011 --> Feb 2012 Recruiting --> Active, not recruiting
- ||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial completion, Trial primary completion date: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Aug 11, 2015
P3, N=106, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Feb 2015
- | Vonjo (pacritinib) / SOBI
Enrollment open: Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (clinicaltrials.gov) - Jul 17, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Feb 2015 Not yet recruiting --> Recruiting
- || fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 30, 2015
P1/2, N=225, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Mar 2015
- luminespib (AUY922) / Ligand
Enrollment change, Trial termination: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Jun 11, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2016 --> Mar 2015 N=25 --> 7 | Active, not recruiting --> Terminated; patient safety
- ||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, Trial primary completion date: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Jun 10, 2015
P3, N=51, Completed, Sponsor: Novartis Pharmaceuticals
N=25 --> 7 | Active, not recruiting --> Terminated; patient safety Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2015
- | imetelstat (GRN163L) / Geron
Trial completion, Enrollment change, Trial primary completion date: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Apr 21, 2015
P2, N=20, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2015 Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013
- |||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial primary completion date: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Apr 20, 2015
P3, N=106, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013 Trial primary completion date: Mar 2015 --> Jun 2015
- ||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Enrollment closed, Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - Apr 20, 2015
P3, N=280, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Mar 2015 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- Jakafi (ruxolitinib) / Novartis, Incyte
Trial primary completion date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Apr 19, 2015
P2, N=28, Suspended, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- | Vonjo (pacritinib) / SOBI
New P2 trial: Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (clinicaltrials.gov) - Apr 7, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment change, Trial primary completion date: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Mar 7, 2015
P3, N=300, Recruiting, Sponsor: Ronald Hoffman
Trial primary completion date: Dec 2014 --> Dec 2015 N=612 --> 300 | Trial primary completion date: Dec 2014 --> Jun 2024
- || Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date: MPD-RC 111: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Mar 7, 2015
P2, N=188, Recruiting, Sponsor: Ronald Hoffman
N=612 --> 300 | Trial primary completion date: Dec 2014 --> Jun 2024 Trial primary completion date: Mar 2015 --> Jun 2018
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2015 --> Jun 2018 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Enrollment closed, Trial primary completion date: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Feb 27, 2015
P3, N=106, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- ||||| Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Feb 11, 2015
P3, N=51, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Feb 5, 2015
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2015
- daunorubicin / Generic mfg., cyclophosphamide / Generic mfg., decitabine / Generic mfg.
Enrollment closed: Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Dec 24, 2014
P2, N=450, Active, not recruiting, Sponsor: Hospital Israelita Albert Einstein
Trial primary completion date: Dec 2013 --> Dec 2015 Recruiting --> Active, not recruiting
- aspirin / Generic mfg., hydroxyurea / Generic mfg.
Enrollment closed, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=1600, Active, not recruiting, Sponsor: University of Cambridge
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2024
- fresolimumab (GC 1008) / Sanofi
Trial termination: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Dec 9, 2014
P1, N=3, Terminated, Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2024 Completed --> Terminated; Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.
- Jakafi (ruxolitinib) / Novartis, Incyte
Trial suspension: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Dec 5, 2014
P2, N=28, Suspended, Sponsor: Mayo Clinic
Completed --> Terminated; Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions. Active, not recruiting --> Suspended
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Enrollment closed: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Nov 28, 2014
P2, N=20, Active, not recruiting, Sponsor: Galena Biopharma, Inc.
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting
- | luminespib (AUY922) / Ligand
Enrollment closed: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Nov 14, 2014
P2, N=25, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion, Trial primary completion date: Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (clinicaltrials.gov) - Nov 14, 2014
P1/2, N=30, Completed, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2013
- | imetelstat (GRN163L) / Geron
Enrollment closed: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Nov 13, 2014
P2, N=40, Active, not recruiting, Sponsor: Geron Corporation
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2013 Suspended --> Active, not recruiting
- |||| Daurismo (glasdegib) / Pfizer
Enrollment open: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Oct 31, 2014
P2, N=221, Recruiting, Sponsor: Pfizer
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- | Jakafi (ruxolitinib) / Incyte
Trial completion, Enrollment change, Trial primary completion date, Tumor mutational burden: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease (clinicaltrials.gov) - Oct 23, 2014
P1, N=49, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=106 --> 49 | Trial primary completion date: May 2015 --> Oct 2014
- || Jakafi (ruxolitinib) / Incyte
Trial primary completion date, Tumor mutational burden: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease (clinicaltrials.gov) - Oct 17, 2014
P1, N=106, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=106 --> 49 | Trial primary completion date: May 2015 --> Oct 2014 Trial primary completion date: Oct 2014 --> May 2015
- fludarabine IV / Generic mfg.
Enrollment closed, Trial primary completion date: Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases (clinicaltrials.gov) - Oct 11, 2014
P2, N=18, Active, not recruiting, Sponsor: Northside Hospital, Inc.
Trial primary completion date: Oct 2014 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Dec 2014
- | Cilcane (cilengitide) / Iceni Pharma
Trial completion, Metastases: EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 17, 2014
P1, N=40, Completed, Sponsor: Indiana University School of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Dec 2014 Active, not recruiting --> Completed
- ||| AZD1480 / AstraZeneca
Trial completion, Tumor mutational burden: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (clinicaltrials.gov) - Sep 12, 2014
P1, N=65, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Daurismo (glasdegib) / Pfizer
Trial primary completion date: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Sep 11, 2014
P2, N=222, Not yet recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Oct 2017
- || gandotinib (LY 2784544) / Eli Lilly
Enrollment closed: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - Sep 11, 2014
P1, N=100, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Sep 9, 2014
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Daurismo (glasdegib) / Pfizer
New P2 trial: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Aug 27, 2014
P2, N=222, Not yet recruiting, Sponsor: Pfizer
- || Jakafi (ruxolitinib) / Incyte
Enrollment closed, Tumor mutational burden: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease (clinicaltrials.gov) - Aug 8, 2014
P1, N=106, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion: American Ginseng in Treating Patients With Fatigue Caused by Cancer (clinicaltrials.gov) - Aug 6, 2014
P3, N=364, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Inrebic (fedratinib) / BMS
Trial completion, Enrollment change: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (clinicaltrials.gov) - Jul 30, 2014
P3, N=289, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=225 --> 289
- |||| Ojjaara (momelotinib) / GSK
Trial completion, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=61, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=225 --> 289 Active, not recruiting --> Completed
- |||| Ojjaara (momelotinib) / GSK
Trial completion: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) - Jul 15, 2014
P2, N=120, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Inrebic (fedratinib) / BMS
Trial completion: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (clinicaltrials.gov) - Jun 27, 2014
P2, N=81, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, P2 data: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) - Jun 22, 2014
P4, N=48, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=100, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Enrollment open: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Jun 17, 2014
P2, N=20, Recruiting, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- |||| Inrebic (fedratinib) / BMS, Jakafi (ruxolitinib) / Incyte
Trial completion: JAKARTA2: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (clinicaltrials.gov) - Jun 12, 2014
P2, N=97, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Inrebic (fedratinib) / BMS, Jakafi (ruxolitinib) / Incyte
Enrollment change: JAKARTA2: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (clinicaltrials.gov) - Jun 9, 2014
P2, N=70, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed N=41 --> 70